Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP)

Launched by ANN & ROBERT H LURIE CHILDREN'S HOSPITAL OF CHICAGO · May 20, 2025

Keywords

ClinConnect Summary

The STAMPP clinical trial is looking at two different ways to treat children with mild community-acquired pneumonia (CAP) who are being cared for at home. The main focus is to see if a "watch and wait" approach, called Safety Net Antibiotic Prescribing (SNAP), can help reduce the use of antibiotics without putting the children’s health at risk. In the SNAP group, parents will give antibiotics only if their child isn’t improving after 72 hours or if they start to get worse. The other group will receive antibiotics right away after their doctor visit. The goal is to figure out which method works better and to understand which types of children benefit most from each approach.

To be eligible for this trial, children must show signs of a respiratory infection and be diagnosed with pneumonia by a doctor, but they should be well enough to be treated at home. Some children may not qualify if they have been hospitalized recently, have certain chronic health conditions, or have other specific health issues. Participants will be followed for 14 days, with surveys conducted at 4, 7, and 14 days to check on their progress. This study aims to help doctors make better decisions about prescribing antibiotics for pneumonia, ensuring that children get the right treatment while helping to reduce unnecessary antibiotic use.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Aims 1 and 2:
• • Presenting with signs and symptoms of lower respiratory tract infection
• • Diagnosed with community-acquired pneumonia (CAP) by a clinician
• • The treating clinician intends to prescribe antibiotics for CAP, AND
• • Well enough, as determined by the clinician at the time of the study enrollment visit, to be managed as an outpatient.
• * Aim 3:
• • Parent/guardian of child enrolled in the trial, OR
• • Clinician who makes prescribing decision at the study site, OR
• • Other practice-based parties (e.g. nurses, pharmacists, medical assistants, practice leaders) at study sites who can comment on the implementation of each prescribing strategy.
• Exclusion Criteria:
• * Aims 1 and 2:
• • Hospitalization within the previous 7 days
• • Oxygen saturation below 90%, if measured
• • Incomplete immunization status (e.g., lacking at least 2 doses of the pneumococcal vaccines, typically given as part of the 2- and 4-month vaccinations)
• • Chronic medical conditions that increase the risk of bacterial CAP (e.g., chronic lung disease, cystic fibrosis, sickle cell disease),\\
• • Substantially immunocompromised status (e.g., immunodeficiency, active cancer treatment, organ transplant with concurrent immunosuppressive agents)
• • Receipt of oral or parenteral antibiotics within the previous 7 days
• • Diagnosis of complicated pneumonia (e.g., empyema, lung abscess)
• • Known bacterial source of infection warranting immediate antibiotics
• • Pneumonia diagnosis within the previous 6 months, OR
• • Prior enrollment in the trial
• • Inability of the parent or guardian to speak English or Spanish
• * Aim 3:
• • Inability of the parent or guardian to speak English